November 30, 2016 / 10:40 PM / a year ago

BRIEF-Bluebird Bio announces interim Phase 1 dose escalation data for anti-BCMA CAR T product candidate

Nov 30 (Reuters) - Bluebird Bio Inc

* Bluebird Bio announces interim phase 1 dose escalation data for its anti-BCMA CAR T product candidate in patients with relapsed/refractory multiple myeloma

* 100% of patients in second and third dose cohorts achieved an objective response Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below